ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
Sai Kiran SharmaKyeara N MackAlessandra PiersigilliJacob PouratKimberly J EdwardsOuti KeinänenMaria S JiaoHuiyong ZhaoBrandy WhiteCory L BrooksElisa De StanchinaMadi R MadiyalakanMichael A HollingsworthPrakash RadhakrishnanJason S LewisBrian M ZeglisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The unique therapeutic mechanism of AR9.6 combined with its excellent in vivo tumor targeting makes it a highly promising theranostic agent. huAR9.6 is poised for clinical translation to impact the management of metastatic ovarian and pancreatic cancers.